TheraRadar
← Back
Data updated: Jul 17, 2026

PHARM RES ASSOC

Pharma
Pharmaceuticals

PHARM RES ASSOC is a pharmaceutical company with 9 FDA-approved products.

1958
Since
9
Drugs
-
Trials
0
New Drugs (2yr)

Upcoming FDA Decisions

Full Calendar →
Aug 10, 2026 — Oveporexton (TAK-861)
23d
Aug 19, 2026 — Garetosmab
Aug 23, 2026 — DTX401 (pariglasgene brecaparvovec)
+2 more dates (Pro)

PHARM RES ASSOC's Key Drugs

PHARM RES ASSOC's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

PHARM RES ASSOC's Recent FDA Approvals

New NDA/BLA approvals for PHARM RES ASSOC over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

PHARM RES ASSOC's Therapeutic Areas

Disease areas where PHARM RES ASSOC has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.

No indication data

PHARM RES ASSOC Pipeline Snapshot

Active clinical trials for PHARM RES ASSOC across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • Top drug revenue breakdown
  • • Drug-level revenue analysis

Trial Catalysts

  • • Active trial monitoring
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling